A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer.
Taiwan
bevacizumab
cetuximab
colorectal cancer
metastatic colorectal cancer
metastectomy
real-world study
target therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
11
2021
accepted:
22
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (
Identifiants
pubmed: 35372058
doi: 10.3389/fonc.2022.808808
pmc: PMC8968042
doi:
Types de publication
Journal Article
Langues
eng
Pagination
808808Informations de copyright
Copyright © 2022 Huang, Lin, Teng, Lin, Chang, Lan, Wang, Yang, Chen and Jiang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neoplasma. 2013;60(5):561-7
pubmed: 23790176
Clin Epidemiol. 2012;4:283-301
pubmed: 23152705
Ann Oncol. 2015 Jun;26(6):1201-1207
pubmed: 25735317
N Engl J Med. 2016 Apr 28;374(17):1605-7
pubmed: 27119236
Int J Cancer. 2019 Jun 15;144(12):2992-3000
pubmed: 30536395
Sci Rep. 2020 Jul 23;10(1):12336
pubmed: 32704062
Cancer Med. 2019 Jul;8(7):3437-3446
pubmed: 31090176
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2020 Oct 20;12(10):
pubmed: 33092032
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2013 Oct;24(10):2554-2559
pubmed: 23864097
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Lancet Oncol. 2016 Oct;17(10):1426-1434
pubmed: 27575024
Clin Oncol (R Coll Radiol). 2019 Sep;31(9):e160-e166
pubmed: 31133363
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959